GeneReach Biotechnology (4171) — Cash Flow Reinvestment Rate
GeneReach Biotechnology (4171) has a Cash Flow Reinvestment Rate of 3.73x as of December 2025, reinvesting NT$44.96 Million (capex NT$4.58 Million plus investments NT$40.39 Million) from operating cash flow of NT$12.05 Million. Explore how much does GeneReach Biotechnology reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
GeneReach Biotechnology Cash Flow Reinvestment Rate (2018–2022)
Historical reinvestment intensity for GeneReach Biotechnology across 4 annual periods. Also explore 4171 total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for GeneReach Biotechnology (2018–2022)
Year-by-year capital reinvestment analysis for GeneReach Biotechnology. For live market cap and broader valuation context, see GeneReach Biotechnology stock valuation.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.26x | NT$92.92 Million | NT$357.63 Million | NT$44.90 Million | ▲ +361.7% |
| 2021 | 0.06x | NT$19.64 Million | NT$348.99 Million | NT$15.79 Million | ▼ -86.1% |
| 2020 | 0.40x | NT$68.72 Million | NT$169.82 Million | NT$64.87 Million | ▼ -62.3% |
| 2018 | 1.07x | NT$6.16 Million | NT$5.74 Million | NT$2.31 Million | — |